U.S. FDA Approves INREBIC® (Fedratinib) as First New Treatment in Nearly a Decade for Patients With Myelofibrosis

Press/Media: Press / Media

PeriodAug 15 2019 → Aug 17 2019

Media coverage

23

Media coverage

  • TitleU.S. FDA Approves INREBIC® (Fedratinib) as First New Treatment in Nearly a Decade for Patients With Myelofibrosis
    Media name/outletPipelineReview
    CountrySpain
    Date8/17/19
    PersonsRuben Mesa
  • TitleU.S. FDA Approves INREBIC® (Fedratinib) as First New Treatment in Nearly a Decade for Patients With Myelofibrosis
    Media name/outletMorningstar.com
    CountryUnited States
    Date8/16/19
    PersonsRuben Mesa
  • TitleU.S. FDA Approves INREBIC® (Fedratinib) as First New Treatment in Nearly a Decade for Patients With Myelofibrosis
    Media name/outletBioSpace
    CountryUnited States
    Date8/16/19
    PersonsRuben Mesa
  • TitleU.S. FDA Approves INREBIC® (Fedratinib) as First New Treatment in Nearly a Decade for Patients With Myelofibrosis
    Media name/outletNasdaq
    CountryUnited States
    Date8/16/19
    PersonsRuben Mesa
  • TitleU.S. FDA Approves INREBIC® (Fedratinib) as First New Treatment in Nearly a Decade for Patients With Myelofibrosis
    Media name/outletMaryville Daily Times
    CountryUnited States
    Date8/16/19
    PersonsRuben Mesa
  • TitleU.S. FDA Approves INREBIC® (Fedratinib) as First New Treatment in Nearly a Decade for Patients With Myelofibrosis
    Media name/outletMarket Newsdesk
    CountryUnited States
    Date8/16/19
    PersonsRuben Mesa
  • TitleU.S. FDA Approves INREBIC® (Fedratinib) as First New Treatment in Nearly a Decade for Patients With Myelofibrosis
    Media name/outletCrwe World
    CountryUnited States
    Date8/16/19
    PersonsRuben Mesa
  • TitleU.S. FDA Approves INREBIC® (Fedratinib) as First New Treatment in Nearly a Decade for Patients With Myelofibrosis
    Media name/outletStocksNewsFeed.com
    CountryUnited States
    Date8/16/19
    PersonsRuben Mesa
  • TitleU.S. FDA Approves INREBIC® (Fedratinib) as First New Treatment in Nearly a Decade for Patients With Myelofibrosis
    Media name/outletCIT
    CountryUnited States
    Date8/16/19
    PersonsRuben Mesa
  • TitleU.S. FDA Approves INREBIC® (Fedratinib) as First New Treatment in Nearly a Decade for Patients With Myelofibrosis
    Media name/outletThe Argus-Press
    CountryUnited States
    Date8/16/19
    PersonsRuben Mesa
  • TitleU.S. FDA Approves INREBIC® (Fedratinib) as First New Treatment in Nearly a Decade for Patients With Myelofibrosis
    Media name/outletMaryville Daily Forum
    CountryUnited States
    Date8/16/19
    PersonsRuben Mesa
  • TitleU.S. FDA Approves INREBIC® (Fedratinib) as First New Treatment in Nearly a Decade for Patients With Myelofibrosis
    Media name/outletSC Now
    CountryUnited States
    Date8/16/19
    PersonsRuben Mesa
  • TitleU.S. FDA Approves INREBIC® (Fedratinib) as First New Treatment in Nearly a Decade for Patients With Myelofibrosis
    Media name/outletValdosta Daily Times
    CountryGeorgia
    Date8/16/19
    PersonsRuben Mesa
  • TitleU.S. FDA Approves INREBIC® (Fedratinib) as First New Treatment in Nearly a Decade for Patients With Myelofibrosis
    Media name/outletHerald Chronicle
    CountryUnited States
    Date8/16/19
    PersonsRuben Mesa
  • TitleU.S. FDA Approves INREBIC® (Fedratinib) as First New Treatment in Nearly a Decade for Patients With Myelofibrosis
    Media name/outletElk Valley Times
    CountryUnited States
    Date8/16/19
    PersonsRuben Mesa
  • TitleU.S. FDA Approves INREBIC® (Fedratinib) as First New Treatment in Nearly a Decade for Patients With Myelofibrosis
    Media name/outletManchester Times
    CountryUnited States
    Date8/16/19
    PersonsRuben Mesa
  • TitleU.S. FDA Approves INREBIC® (Fedratinib) as First New Treatment in Nearly a Decade for Patients With Myelofibrosis
    Media name/outletLudington Daily News
    CountryUnited States
    Date8/16/19
    PersonsRuben Mesa
  • TitleU.S. FDA Approves INREBIC® (Fedratinib) as First New Treatment in Nearly a Decade for Patients With Myelofibrosis
    Media name/outletTullahoma News
    CountryUnited States
    Date8/16/19
    PersonsRuben Mesa
  • TitleU.S. FDA Approves INREBIC® (Fedratinib) as First New Treatment in Nearly a Decade for Patients With Myelofibrosis
    Media name/outletDaily American
    CountryUnited States
    Date8/16/19
    PersonsRuben Mesa
  • TitleU.S. FDA Approves INREBIC® (Fedratinib) as First New Treatment in Nearly a Decade for Patients With Myelofibrosis
    Media name/outletGalveston County Daily News
    CountryUnited States
    Date8/16/19
    PersonsRuben Mesa
  • TitleU.S. FDA Approves INREBIC® (Fedratinib) as First New Treatment in Nearly a Decade for Patients With Myelofibrosis
    Media name/outletErie News Now
    CountryUnited States
    Date8/16/19
    PersonsRuben Mesa
  • TitleU.S. FDA Approves INREBIC® (Fedratinib) as First New Treatment in Nearly a Decade for Patients With Myelofibrosis
    Media name/outletCW WBCB
    CountryUnited States
    Date8/16/19
    PersonsRuben Mesa
  • TitleU.S. FDA Approves INREBIC® (Fedratinib) as First New Treatment in Nearly a Decade for Patients With Myelofibrosis
    Media name/outletAcrofan
    Date8/15/19
    PersonsRuben Mesa